Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618
This examiner grants 68% of resolved cases
Jagadishwar Rao Samala has resolved 795 cases in Tech Center 1600. The examiner maintains an allowance rate of 67.9 percent. This rate provides a baseline for success in Art Unit 1618. The high volume of cases suggests that the 67.9 percent rate is a reliable indicator of the examiner's standard practice.
The interview lift is 55.6 percent. This is an exceptionally high lift, indicating that interviews are a critical strategy for securing an allowance. A lift of 55.6 percent suggests that the examiner is very responsive to the arguments and clarifications provided during a personal meeting. Practitioners should consider an interview as a primary tool in their prosecution strategy.
The median days to allowance is 1175. This duration reflects the typical time required to navigate the examination process to a successful conclusion. Given the high 55.6 percent interview lift, scheduling a meeting early in the process may help manage the 1175 day pendency more effectively.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18772628 | PSMA-BINDING AGENTS AND USES THEREOF | Non-Final OA | The Johns Hopkins University |
| 18754996 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | Non-Final OA | The Johns Hopkins University |
| 18577453 | COMPOSITIONS AND METHODS RELATING TO CELLS WITH ADHERED PARTICLES | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18628570 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Final Rejection | NOVARTIS AG |
| 18440783 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Non-Final OA | NOVARTIS AG |
| 18575997 | METHOD FOR EVALUATING A COSMETIC COMPOSITION OR COMPONENT THEREOF | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 18686456 | PURIFIED SIGNAL-ENHANCED CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | Non-Final OA | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E. V. |
| 18779607 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | Non-Final OA | Cornell University |
| 17979367 | NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Final Rejection | BAYER PHARMA AKTIENGESELLSCHAFT |
| 18687804 | INHIBITOR OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND PHARMACEUTICAL USE THEREOF | Non-Final OA | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. |
| 18554500 | A MULTIOMIC APPROACH TO MODELING OF GENE REGULATORY NETWORKS IN MULTIPLE MYELOMA | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy